Eli Lilly and Company

LLY

NYSE

805.43

USD

+6.54(+0.82%)

As of today

Overview Financials Dividends Ratios Discussions Analysis

Eli Lilly and Company fundamentals

Overview Income Statement Balance Sheet Cash Flow

Key ratios

P/E Ratio

65.38

Price/Book

46.33

Debt/Equity

244.32%

Return on Equity

76.92%

Dividend Yield

0.69%

EBITDA

15.23B

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Statements Highlights

AnnualQuarterly

Period Ending	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024
Total Revenue	24,539,800,000	28,318,400,000	28,541,400,000	34,124,100,000	45,042,700,000
Gross Profit	19,056,500,000	21,005,600,000	21,911,600,000	27,041,900,000	36,624,400,000
Operating Income	7,210,800,000	7,933,000,000	8,653,300,000	10,787,300,000	17,501,700,000
Net Income	6,193,700,000	5,581,700,000	6,244,800,000	5,240,400,000	10,590,000,000
Total Assets	46,633,100,000	48,806,000,000	49,489,800,000	64,006,300,000	78,714,900,000
Total Current Liabilities	12,481,600,000	15,052,700,000	17,138,200,000	27,293,200,000	28,376,600,000
Total Equity	5,825,200,000	9,154,800,000	10,775,400,000	10,863,700,000	14,271,600,000
Free Cash Flow	4,470,500,000	5,387,500,000	4,600,400,000	-3,152,000,000	414,300,000
Cash from Operations	6,499,600,000	7,365,900,000	7,585,700,000	4,240,100,000	8,817,900,000
Cash from Investing	-2,258,900,000	-2,867,500,000	-3,762,900,000	-7,152,700,000	-9,301,500,000
Cash from Financing	-3,137,100,000	-4,131,300,000	-5,406,700,000	3,495,600,000	1,230,100,000
Net Change in Cash	1,319,600,000	161,400,000	-1,751,500,000	751,600,000	449,800,000

Eli Lilly and Company

LLY

805.43

Eli Lilly and Company fundamentals

Key ratios

Statements Highlights

Dividends

Analyst Recomendations